Tempest Therapeutics Holds Annual Stockholder Meeting

• Tempest Therapeutics shareholders approved potential issuance of 20% or more of outstanding common stock to Lincoln Park on November 9, 2026.
• Shareholders authorized up to 3,105,591 common shares each underlying outstanding Series C Warrants and Series D Warrants under the PIPE proposal.
• The PIPE approval also covered up to 217,391 common shares underlying placement agent warrants issued to H.C. Wainwright designees.
• John David Yee and William Drake Richey were elected Class II directors.
• Ernst & Young was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-118006), on November 10, 2026, and is solely responsible for the information contained therein.